In cancer drug therapy the aim is generally a downregulation of mTOR and Hsf1, whereas in healthy aging an increased Hsf1 activity should potentially be beneficial in that it will increase chaperone levels, thereby causing the improved proteostasis that could counteract sarcopenia and neurodegenerative disease [3, 10]. Here, HSF1 is linked to cancer.